BHARAT IMMUNOLOGICALS (India) Performance

The firm owns Beta (Systematic Risk) of 0.0 which signifies that the returns on MARKET and BHARAT IMMUNOLOGICALS are completely uncorrelated. Although it is extremely important to respect BHARAT IMMUNOLOGICALS existing price patterns, it is better to be realistic regarding the information on equity price patterns. The approach to foreseeing future performance of any stock is to evaluate the business as a whole together with its past performance including all available fundamental and technical indicators. By examining BHARAT IMMUNOLOGICALS technical indicators you can at this time evaluate if the expected return of 0.0% will be sustainable into the future. BHARAT IMMUNOLOGICALS at this moment owns a risk of 0.0%. Please confirm BHARAT IMMUNOLOGICALS BIOLOG Jensen Alpha, Semi Variance and the relationship between Standard Deviation and Value At Risk to decide if BHARAT IMMUNOLOGICALS BIOLOG will be following its current price history.
00

Risk-Adjusted Performance

Over the last 30 days BHARAT IMMUNOLOGICALS BIOLOG has generated negative risk-adjusted returns adding no value to investors with long positions. Despite somewhat strong basic indicators, BHARAT IMMUNOLOGICALS is not utilizing all of its potentials. The current stock price disturbance, may contribute to short term losses for the investors.
Fifty Two Week Low5.75
Fifty Two Week High20.20
Horizon     30 Days    Login   to change

BHARAT IMMUNOLOGICALS Relative Risk vs. Return Landscape

If you would invest (100.00)  in BHARAT IMMUNOLOGICALS BIOLOG on October 18, 2019 and sell it today you would earn a total of  100.00  from holding BHARAT IMMUNOLOGICALS BIOLOG or generate -100.0% return on investment over 30 days. BHARAT IMMUNOLOGICALS BIOLOG is generating negative expected returns and assumes 0.0% volatility on return distribution over the 30 days horizon. Simply put, 0% of equities are less volatile than BHARAT IMMUNOLOGICALS and 99% of equity instruments are likely to generate higher returns than the company over the next 30 trading days.
 Daily Expected Return (%) 
      Risk (%) 

BHARAT IMMUNOLOGICALS Market Risk Analysis

Sharpe Ratio = 0.0
Best
Portfolio
Best
Equity
Good Returns
Average Returns
Small Returns
CashSmall
Risk
Average
Risk
High
Risk
Huge
Risk
BIBCL
Based on monthly moving average BHARAT IMMUNOLOGICALS is performing at about 0% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of BHARAT IMMUNOLOGICALS by adding it to a well-diversified portfolio.

BHARAT IMMUNOLOGICALS Alerts

Equity Alerts and Improvement Suggestions

BHARAT IMMUNOLOGICALS is not yet fully synchronised with the market data
BHARAT IMMUNOLOGICALS has some characteristics of a very speculative penny stock
The company reported revenue of 836.45 M. Net Loss for the year was (55.57 M) with profit before overhead, payroll, taxes, and interest of 103.65 M.
See also Trending Equities. Please also try Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Search macroaxis.com